NCT02870569View on ClinicalTrials.gov

Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

July 2, 2018

Study Completion Date

December 31, 2018

Conditions
Differentiated Thyroid Cancer
Interventions
DRUG

Donafenib 200mg

Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects.The arm is the lower dose one.

DRUG

Donafenib 300mg

Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects.The arm is the higher dose one.

Trial Locations (1)

Unknown

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY

NCT02870569 - Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer | Biotech Hunter | Biotech Hunter